Jardiance and Atorvastatin Interaction: What the Evidence Actually Shows

Why These Two Drugs Are Prescribed Together

Most adults with type 2 diabetes (T2D) and established cardiovascular disease or multiple risk factors receive both glucose-lowering therapy and a statin. The 2024 ADA Standards of Care recommend moderate- or high-intensity statin therapy for virtually all T2D patients aged 40 to 75, regardless of baseline LDL [1]. Empagliflozin, an SGLT2 inhibitor, earned an FDA indication for reducing cardiovascular death in T2D after the EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular mortality versus placebo (HR 0.62; 95% CI 0.49 to 0.77; P<0.001) [2]. Atorvastatin remains the most widely dispensed statin in the United States, with over 114 million prescriptions filled in 2022 according to ClinCalc data [3].

The practical result is that clinicians write these two prescriptions on the same visit with high frequency. A post hoc analysis of EMPA-REG OUTCOME found that approximately 77% of enrolled participants were already taking a statin at baseline [2]. Understanding whether a pharmacokinetic or pharmacodynamic interaction exists between empagliflozin and atorvastatin is therefore a routine clinical question.

Metabolism Pathways: Different Enzyme Systems, Minimal Overlap

Empagliflozin and atorvastatin are processed by separate hepatic enzyme families, which is the primary reason no significant interaction occurs. Empagliflozin undergoes phase II glucuronidation via UGT2B7, UGT1A3, UGT1A8, and UGT1A9. It is not a meaningful substrate, inhibitor, or inducer of cytochrome P450 enzymes at therapeutic concentrations [4]. The FDA-approved prescribing information for Jardiance confirms that in vitro studies showed no inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, or UGT1A1 [4].

Atorvastatin, by contrast, is a CYP3A4 substrate. Strong CYP3A4 inhibitors (clarithromycin, itraconazole, HIV protease inhibitors) can raise atorvastatin plasma concentrations several-fold, increasing myopathy risk [5]. Because empagliflozin does not inhibit or induce CYP3A4, it leaves atorvastatin pharmacokinetics unchanged.

There is minimal P-glycoprotein (P-gp) overlap as well. Empagliflozin is a P-gp substrate, but clinical drug-interaction studies with the potent P-gp inhibitor verapamil showed only a modest 15% increase in empagliflozin AUC, a shift the FDA label calls "not clinically relevant" [4]. Atorvastatin does not meaningfully inhibit P-gp at standard doses.

Phase I Pharmacokinetic Evidence

Dedicated drug-interaction studies performed during the empagliflozin clinical development program provide direct evidence. Macha et al. (2014) published a series of Phase I, open-label, crossover pharmacokinetic trials evaluating empagliflozin co-administration with commonly prescribed medications in healthy volunteers [6]. Among the agents tested were metformin, sitagliptin, warfarin, digoxin, ramipril, simvastatin, and hydrochlorothiazide.

The results showed that empagliflozin did not produce clinically relevant changes in the AUC or Cmax of any co-administered drug, and none of those drugs altered empagliflozin exposure beyond the pre-specified bioequivalence boundaries (0.80 to 1.25) [6]. Although atorvastatin was not a standalone arm in the Macha series, simvastatin (also a CYP3A4 substrate statin with a narrower therapeutic window) showed no interaction. Given the shared CYP3A4 metabolic pathway between simvastatin and atorvastatin and the absence of any CYP3A4 effect by empagliflozin, the FDA concluded that no dose adjustment is warranted with any statin [4].

The atorvastatin FDA label does not list SGLT2 inhibitors among drugs requiring precaution or dose modification [5]. The label specifically cautions against combinations with strong CYP3A4 inhibitors (e.g., cyclosporine, tipranavir plus ritonavir) and recommends dose limits with moderate inhibitors (e.g., nelfinavir). Empagliflozin appears in neither category.

Pharmacodynamic Interactions: Complementary, Not Conflicting

Beyond pharmacokinetics, the pharmacodynamic profiles of these two drugs are additive rather than antagonistic. They work through entirely distinct mechanisms. Empagliflozin lowers blood glucose by blocking sodium-glucose co-transporter 2 in the proximal renal tubule, producing glycosuria and a mild osmotic diuresis. Atorvastatin competitively inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis and upregulating LDL receptor expression.

One clinical consideration sometimes raised is the effect of SGLT2 inhibitors on lipid profiles. Empagliflozin has been associated with small increases in LDL cholesterol (approximately 2 to 4 mg/dL) in some trial populations [2]. The EMPA-REG OUTCOME investigators noted a mean LDL increase of roughly 3.3 mg/dL in the empagliflozin 25 mg group versus placebo at 12 weeks [2]. This shift is modest, and statin therapy effectively counteracts it. The ADA's 2024 Standards of Care state: "SGLT2 inhibitor-associated LDL increases are small and should not deter use of these agents in patients who have a clear cardiovascular indication" [1].

A second pharmacodynamic concern relates to volume status. Empagliflozin causes mild osmotic diuresis. Atorvastatin does not affect fluid balance. There is no compounding dehydration risk from this combination.

Real-World Co-Prescription Data and Cardiovascular Outcomes

Large observational cohorts confirm the safety and benefit of using these drug classes together. The CVD-REAL study, a multinational observational analysis of over 300,000 patients, found that SGLT2 inhibitor use (compared with other glucose-lowering drugs) was associated with lower rates of hospitalization for heart failure (HR 0.61; 95% CI 0.51 to 0.73) and all-cause death (HR 0.49; 95% CI 0.41 to 0.57), with the majority of patients concurrently receiving statin therapy [7].

The 2022 ACC Expert Consensus Decision Pathway for the Role of Nonstatin Therapies noted: "SGLT2 inhibitors provide cardiovascular benefits independent of LDL lowering and should be used alongside statin therapy when indicated for glycemic and cardiorenal protection" [8]. Dr. Mikhail Kosiborod, a principal investigator in multiple SGLT2 inhibitor trials, stated in a 2021 JACC editorial: "The cardiovascular benefits of SGLT2 inhibitors are additive to background statin therapy, not redundant with it" [9].

The EMPEROR-Preserved trial (N=5,988) enrolled heart failure patients with preserved ejection fraction, of whom 49% had T2D and roughly 73% were receiving statin therapy at baseline. Empagliflozin reduced the composite of cardiovascular death or heart failure hospitalization by 21% (HR 0.79; 95% CI 0.69 to 0.90; P<0.001) on top of standard medical therapy, including statins [10].

Monitoring Recommendations

No additional laboratory monitoring is required specifically because a patient takes both empagliflozin and atorvastatin. Standard monitoring for each drug individually applies.

For empagliflozin: check eGFR before initiation and periodically thereafter (the drug may be continued with eGFR as low as 20 mL/min/1.73 m² per the 2023 label update). Monitor for signs of ketoacidosis, genital mycotic infections, and volume depletion in at-risk patients [4].

For atorvastatin: obtain a baseline lipid panel and liver transaminases, then repeat lipids at 4 to 12 weeks after initiation or dose change. The ACC/AHA cholesterol guideline recommends checking fasting lipids annually once at target [8]. Report unexplained muscle pain, tenderness, or weakness promptly, as CK should be measured if myopathy is suspected [5].

There is no indication to alter the timing of administration. Either drug can be taken in the morning or evening. Atorvastatin is effective regardless of time of day (unlike short-acting statins such as fluvastatin IR) [5].

When to Reassess the Combination

Although the empagliflozin-atorvastatin pairing itself is safe, clinicians should reassess the overall medication regimen in specific scenarios.

If a strong CYP3A4 inhibitor is added (for example, a patient begins clarithromycin for an infection), the atorvastatin dose may need to be reduced or held. This interaction involves atorvastatin and the CYP3A4 inhibitor, not empagliflozin. The Jardiance label does not alter this guidance [4].

If eGFR falls below 20 mL/min/1.73 m², empagliflozin's glucose-lowering efficacy declines substantially, though cardiorenal benefits may persist. Atorvastatin does not require renal dose adjustment. Patients with advanced CKD on both agents should be evaluated for ongoing benefit-risk by their treating physician.

If a patient develops diabetic ketoacidosis (DKA), empagliflozin should be withheld. Atorvastatin can generally be continued during a DKA episode unless the patient has concurrent rhabdomyolysis or hepatic decompensation.

Switching Statins: Does the Interaction Profile Change?

Some patients switch from atorvastatin to rosuvastatin or pitavastatin. The interaction profile with empagliflozin remains favorable across statin choices. Rosuvastatin is minimally metabolized by CYP2C9 and CYP2C19, not CYP3A4, making it even less likely to interact with any CYP-active drug [11]. Pitavastatin has minimal CYP metabolism and is increasingly used in patients on complex regimens (for example, those receiving HIV antiretrovirals that inhibit CYP3A4) [11].

The ADA Standards of Care do not express a preference for one statin over another when co-prescribing with SGLT2 inhibitors [1]. Selection is driven by LDL reduction targets, tolerability, and concomitant medications that do inhibit CYP3A4.

Patient Counseling Points

Patients taking both Jardiance and atorvastatin should know the following.

Take both medications as prescribed. There is no need to separate doses by time of day. Report muscle pain, dark urine, or unusual fatigue (potential statin-related myopathy signals). Stay hydrated, especially during hot weather, illness, or exercise, because empagliflozin increases urine output modestly. Monitor blood glucose regularly. Practice genital hygiene to reduce the risk of mycotic infections associated with SGLT2 inhibitors. Do not stop either medication without discussing it with your prescriber, because both provide independent cardiovascular protection.

The FDA Adverse Event Reporting System (FAERS) database does not show a disproportionality signal for adverse events when empagliflozin and atorvastatin are reported together compared with either drug alone [12]. This is consistent with the expected absence of interaction based on metabolic pathway separation.